Jocelyn Aspa

Jocelyn obtained her diploma in journalism from Langara College in April 2016, just prior to joining INN as a staff writer for the resource sector. Since then, Jocelyn has shifted to covering the life science space and has become managing editor for INN's technology, cannabis and life science divisions. Jocelyn is passionate about niche topics within the life science sector and enjoys shedding light on companies focused on unmet clinical needs.

Prior to joining INN, Jocelyn interned at the Georgia Straight and blogged about the Vancouver Canucks. Before following her career in journalism, Jocelyn spent several years working in law firms. She thrives off the knowledge her background brings to her reporting.

jaspa@investingnews.com

Articles

Pharma Market Update: Q3 2019 in Review

With Q3 2019 officially over, the Investing News Network shares a pharma market update on the biggest news and trends...

October 15th, 2019

5 Top NASDAQ Biotech and Pharma Stocks: Jounce Rises Over 20 Percent

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...

October 13th, 2019

Auris Medical Releases Results from MAP US2 Open-Label Extension Study

The company announced results from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and somnolence.

October 11th, 2019

RedHill Biopharma Releases Positive Results from MAP US Phase 3 Study

The company announced positive results from its MAP US Phase 3 Study and MAP US2 Open-Label Extension Study

October 11th, 2019

3 Top Pharma Stocks on the TSX and TSXV Year-to-Date

With three quarters of the year over, it's time to look back on the top-performing pharma stocks on the TSX...

October 10th, 2019

ProQR Announces Positive Phase 1/2 Study of Sepofarsen

The company announced topline results for its PQ-110-001 study in patients with Leber's congenital amaurosis 10 (LCA10).

October 10th, 2019

Krystal Biotech Receives EMA Opinion on KB105

The company's KB105 treatment was previously approved by the US Food and Drug Administration in August 2018.

October 10th, 2019